<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30486733</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8069</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <PubDate>
              <Year>2019</Year>
              <Season>Jan-Dec</Season>
            </PubDate>
          </JournalIssue>
          <Title>Molecular pain</Title>
          <ISOAbbreviation>Mol Pain</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers.</ArticleTitle>
        <Pagination>
          <StartPage>1744806918819944</StartPage>
          <MedlinePgn>1744806918819944</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">1744806918819944</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/1744806918819944</ELocationID>
        <Abstract>
          <AbstractText>Fibromyalgia is a disease characterized by chronic widespread pain with additional symptoms, such as joint stiffness, fatigue, sleep disturbance, cognitive dysfunction, and depression. Currently, fibromyalgia diagnosis is based exclusively on a comprehensive clinical assessment, according to 2016 ACR criteria, but validated biological biomarkers associated with fibromyalgia have not yet been identified. Genome-wide association studies investigated genes potentially involved in fibromyalgia pathogenesis highlighting that genetic factors are possibly responsible for up to 50% of the disease susceptibility. Potential candidate genes found associated to fibromyalgia are SLC64A4, TRPV2, MYT1L, and NRXN3. Furthermore, a gene-environmental interaction has been proposed as triggering mechanism, through epigenetic alterations: In particular, fibromyalgia appears to be characterized by a hypomethylated DNA pattern, in genes implicated in stress response, DNA repair, autonomic system response, and subcortical neuronal abnormalities. Differences in the genome-wide expression profile of microRNAs were found among multiple tissues, indicating the involvement of distinct processes in fibromyalgia pathogenesis. Further studies should be dedicated to strength these preliminary findings, in larger multicenter cohorts, to identify reliable directions for biomarker research and clinical practice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>D'Agnelli</LastName>
            <ForeName>Simona</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-5396-9542</Identifier>
            <AffiliationInfo>
              <Affiliation>1 Anesthesiology, Critical Care and Pain Medicine Division, Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arendt-Nielsen</LastName>
            <ForeName>Lars</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>2 Department of Health Science and Technology, Aalborg University, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gerra</LastName>
            <ForeName>Maria C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>2 Department of Health Science and Technology, Aalborg University, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zatorri</LastName>
            <ForeName>Katia</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>1 Anesthesiology, Critical Care and Pain Medicine Division, Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boggiani</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>3 Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baciarello</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>1 Anesthesiology, Critical Care and Pain Medicine Division, Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bignami</LastName>
            <ForeName>Elena</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>1 Anesthesiology, Critical Care and Pain Medicine Division, Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Pain</MedlineTA>
        <NlmUniqueID>101242662</NlmUniqueID>
        <ISSNLinking>1744-8069</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057890" MajorTopicYN="N">Epigenomics</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005356" MajorTopicYN="Y">Fibromyalgia</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005823" MajorTopicYN="Y">Genetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">DNA methylation</Keyword>
        <Keyword MajorTopicYN="Y">Fibromyalgia</Keyword>
        <Keyword MajorTopicYN="Y">biomarkers</Keyword>
        <Keyword MajorTopicYN="Y">epigenetics</Keyword>
        <Keyword MajorTopicYN="Y">genetics</Keyword>
        <Keyword MajorTopicYN="Y">genome-wide association study</Keyword>
        <Keyword MajorTopicYN="Y">miRNAs</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30486733</ArticleId>
        <ArticleId IdType="pmc">PMC6322092</ArticleId>
        <ArticleId IdType="doi">10.1177/1744806918819944</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jones GT, Atzeni F, Beasley M, FluB E, Sarzi-Puttini P, Macfarlane GJ.
The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria.
Arthritis Rheumatol
2015; 
67: 568–575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25323744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi DH and, Kim HS.
Quantitative analysis of nailfold capillary morphology in patients with fibromyalgia.
Korean J Intern Med
2015; 
30: 531–537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4497341</ArticleId>
            <ArticleId IdType="pubmed">26161020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Son CN, Kim SH, Chang HW and, Kim JM.
A neurometabolite study of chronic daily headache in patients with systemic lupus erythematosus using magnetic resonance spectroscopy: comparison with fibromyalgia patients and healthy controls.
Korean J Intern Med
2016; 
31: 1171–1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5094926</ArticleId>
            <ArticleId IdType="pubmed">27017392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clauw DJ.
Fibromyalgia: a clinical review.
JAMA
2014; 
311: 1547–1555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24737367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prados G, Miró E, Martínez MP, Sánchez AI, López S and, Sáez G.
Fibromyalgia: gender differences and sleep-disordered breathing. Clin Exp Rheumatol
2013; 
31: S102–S110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24373368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe F, Ross K, Anderson J and, Russell IJ.
Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms.
J Rheumatol
1995; 
22: 151–156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7699662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradley LA.
Pathophysiology of fibromyalgia.
Am J Med
2009; 
122: S22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2821819</ArticleId>
            <ArticleId IdType="pubmed">19962493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branco JC.
State-of-the-art on fibromyalgia mechanism.
Acta Reumatol Port
2010; 
35: 10–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20505625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek SH, Seok HY, Koo YS, Kim BJ.
Lengthened cutaneous silent period in fibromyalgia suggesting central sensitization as a pathogenesis.
PLoS One
2016; 
11: e0149248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4752484</ArticleId>
            <ArticleId IdType="pubmed">26871583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosek E and, Hansson P.
Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects.
Pain
1997; 
70: 41–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9106808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Julien N, Goffaux P, Arsenault P, Marchand S.
Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition.
Pain
2005; 
114: 295–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15733656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sluka KA.
Neurobiology of fibromyalgia and chronic widespread pain.
Neuroscience
2016; 
338: 114–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5083139</ArticleId>
            <ArticleId IdType="pubmed">27291641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Brien AT, Deitos A, Triñanes Pego Y.
. Defective endogenous pain modulation in fibromyalgia: a meta-analysis of temporal summation and conditioned pain modulation paradigms. J Pain
2018; 
19: 819–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29454976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Millan MJ.
Descending control of pain.
Prog Neurobiol
2002; 
66: 355–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12034378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG.
Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception.
Brain Res
2003; 
987: 176–185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14499961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loggia LM Berna C Kim J Cahalan CM Gollub RL Wasan AD Harris RE Edwards RE, andNapadow V.. 
Disrupted brain circuitry for pain‐related reward/punishment in fibromyalgia.
Arthritis Rheumatol
2014; 
66: 203–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4516215</ArticleId>
            <ArticleId IdType="pubmed">24449585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gracely RH Petzke F Wolf JM, andClauw DJ.. 
Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia.
Arthritis Rheum
2002; 
46: 1333–1343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12115241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe F Smythe HA Yunus MB, andBennett RM.. 
The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee.
Arthritis Rheum
1990; 
33: 160–172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2306288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe F Clauw DJ Fitzcharles MA Goldenberg DL Katz RS Mease P Russell AS Russell IJ Winfield JB, andYunus MB.. 
The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.
Arthritis Care Res
2010; 
62: 600–610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20461783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe F Clauw DJ Fitzcharles MA Goldenberg DL Häuser W Katz RL Mease PJ Russell AS Russell IJ, andWalitt B.. 
2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.
Semin Arthritis Rheum
2016; 
46: 319–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27916278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ablin JN, Buskila D.
Update on the genetics of the fibromyalgia syndrome.
Best Pract Res Clin Rheumatol
2015; 
29: 20–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26266996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mogil JS.
Pain genetics: past, present and future.
Trends Genet
2012; 
28: 258–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22464640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oertel B, Lotsch J.
Genetic mutations that prevent pain: implications for future pain medication.
Pharmacogenomics
2008; 
9: 179–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18370847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold LM Fan J Russell IJ Yunus MB Khan MA Kushner I Olson JM, andIyengar SK.. 
The fibromyalgia family study: a genome-wide linkage scan study.
Arthritis Rheum
2013; 
65:1122–1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3618544</ArticleId>
            <ArticleId IdType="pubmed">23280346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mergener M Becker RM dos Santos AF dos Santos GA, andde Andrade FM.. 
Influence of the interaction between environmental quality and T102C SNP in the HTR2A gene on fibromyalgia susceptibility.
Rev Bras Reumatol
2011; 
51: 594–602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22124593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen H, Buskila D, Neumann L, Ebstein RP.
Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5‐ HTTLPR) polymorphism, and relationship to anxiety‐related personality traits.
Arthritis Rheum
2002; 
46: 845–847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11920428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mickle AD, Shepherd AJ, Mohapatra DP.
Sensory TRP channels: the key transducers of nociception and pain.
Prog Mol Biol Transl Sci
2015; 
131: 73–118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5903472</ArticleId>
            <ArticleId IdType="pubmed">25744671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernández-de-Las-Peñas C Ambite-Quesada S Gil-Crujera A Gil-Crujera A Cigarán-Méndez M, andPeñacoba-Puente C.. 
Catechol-O-methyltransferase Val158Met polymorphism influences anxiety, depression, and disability, but not pressure pain sensitivity, in women with fibromyalgia syndrome.
J Pain
2012; 
13: 1068–1074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23025981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vargas-Alarcón G Fragoso JM Cruz-Robles D Vargas A Martinez A Lao-Villadóniga JI García-Fructuoso F Vallejo M, andMartínez-Lavín M.. 
Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains.
Arthritis Rheum
2009; 
60: 2169–2173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19565482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gürsoy S Erdal E Herken H Madenci E, andAlaşehirli B.. 
Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome.
Rheumatol Int
2001; 
21: 58–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11732859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YH Choi SJ Ji JD, andSong GG.. 
Candidate gene studies of fibromyalgia: a systematic review and meta-analysis.
Rheumatol Int
2012; 
32: 417–426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21120487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Docampo E Escaramis G Gratacos M Villatoro S Puig A Kogevinas M Collado A Carbonell J Rivera J Vidal J Alegre J Estivill X, andRabionet R.. 
Genome-wide analysis of single nucleotide polymorphisms and copy number variants in fibromyalgia suggest a role for the central nervous system.
Pain
2014; 
155: 1102–1109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24582949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith SB Maixner DW Fillingim RB Slade G Gracely RH Ambrose K Zaykin DV Hyde C John S Tan K Maixner W, andDiatchenko L.. 
Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia.
Arthritis Rheum
2012; 
64: 584–593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3237946</ArticleId>
            <ArticleId IdType="pubmed">21905019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood PB Schweinhardt P Jaeger E Dagher A Hakyemez H Rabiner EA Bushnell MC, andChizh BA.. 
Fibromyalgia patients show an abnormal dopamine response to pain.
Eur J Neurosci
2007; 
25: 3576–3582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17610577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gold SJ, Ni YG, Dohlman HG, Nestler EJ.
Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain.
J Neurosci
1997; 
17: 8024–8037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793903</ArticleId>
            <ArticleId IdType="pubmed">9315921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juhasz G Lazary J Chase D Pegg E Downey D Toth ZG Stones K Platt H Mekli K Payton A Anderson IM Deakin JF, andBagdy G.. 
Variations in the cannabinoid receptor 1 gene predispose to migraine.
Neurosci Lett
2009; 
461: 116–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19539700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park JM Choi M-G Cho YK Lee IS Kim SW Choi KY, andChung IS.. 
Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study.
J Clin Gastroenterol
2011; 
45: 45–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20505532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu AT Ogdie MN Järvelin M-R Moilanen IK Loo SK McCracken JT McGough JJ Yang MH Peltonen L Nelson SF Cantor RM, andSmalley SL.. 
Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder.
Am J Med Genet B Neuropsychiatr Genet
2008; 
147B: 1488–1494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2685476</ArticleId>
            <ArticleId IdType="pubmed">18213623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleakman D, Alt A, Nisenbaum ES.
Glutamate receptors and pain.
Sem Cell Dev Biol Pain
2006; 
17: 592–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17110139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vargas-Alarcón G Fragoso JM Cruz-Robles D Vargas A Vargas A Lao-Villadóniga JI García-Fructuoso F Ramos-Kuri M Hernández F Springall R Bojalil R Vallejo M, andMartínez-Lavín M.. 
Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia.
Arthritis Res Ther
2007; 
9: R110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2212567</ArticleId>
            <ArticleId IdType="pubmed">17961261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vargas-Alarcón G Fragoso JM Cruz-Robles D Vargas A Martinez A Lao-Villadóniga JI García-Fructuoso F Vallejo M, andMartínez-Lavín M.. 
Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains.
Arthritis Rheum
2009; 
60: 2169–2173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19565482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Allaf AW Dunbar KL Hallum NS Nosratzadeh B Templeton KD, andPullar T.. 
A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome.
Rheumatology
2002; 
41: 450–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11961177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gur A Kaeakoc M Nas K Remzi Cevik Denli A, andSaraç J.. 
Cytokines and depression in cases with fibromyalgia. J Rheumatol
2002; 
29: 358–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11838856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Low LA, Schweinhardt P.
Early life adversity as a risk factor for fibromyalgia in later life.
Pain Res Treat
2012; 
2012: 140832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3196867</ArticleId>
            <ArticleId IdType="pubmed">22110940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klingmann PO Kugler I Steffke TS Bellingrath S Kudielka BM, andHellhammer DH.. 
Sex-speciﬁc prenatal programming: a risk for ﬁbromyalgia?
Ann N Y Acad Sci
2008; 
1148: 446–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19120140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paras ML Murad MH Chen LP Goranson EN Sattler AL Colbenson KM Elamin MB Seime RJ Prokop LJ, andZirakzadeh A.. 
Sexual abuse and lifetime diagnosis of somatic disorders: a systematic review and meta-analysis.
JAMA
2009; 
302: 550–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19654389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Häuser W Kosseva M Üceyler N Klose P, andSommer C.. 
Emotional, physical, and sexual abuse in ﬁbromyalgia syndrome: a systematic review with meta-analysis.
Arthritis Care Res
2011; 
63: 808–820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20722042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Low LA, Schweinhardt P.
Early life adversity as a risk factor for fibromyalgia in later life.
Pain Res Treat
2012; 
2012: 140832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3196867</ArticleId>
            <ArticleId IdType="pubmed">22110940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tikkanen R Ducci F Goldman D Holi M Lindberg N Tiihonen J, andVirkkunen M.. 
MAOA alters the eﬀects of heavy drinking and childhood physical abuse on risk for severe impulsive acts of violence among alcoholic violent oﬀenders.
Alcohol Clin Exp Res
2010; 
34: 853–860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195419</ArticleId>
            <ArticleId IdType="pubmed">20201935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harkness EF Macfarlane GJ Nahit E Silman AJ, andMcBeth J.. 
Mechanical injury and psychosocial factors in the work place predict the onset of widespread body pain: a two-year prospective study among cohorts of newly employed workers.
Arthritis Rheum
2004; 
50: 1655–1664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15146437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett RM Jones J Turk DC Russell IJ, andMatallana L.. 
An internet survey of 2,596 people with fibromyalgia.
BMC Musculoskelet Disord
2007; 
8: 27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1829161</ArticleId>
            <ArticleId IdType="pubmed">17349056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haviland MG Morton KR Oda K, andFraser GE.. 
Traumatic experiences, major life stressors, and self-reporting a physician-given fibromyalgia diagnosis.
Psychiatry Res
2010; 
177: 335–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2868959</ArticleId>
            <ArticleId IdType="pubmed">20382432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hellou R Häuser W Brenner I Buskila D Jacob G Elkayam O Aloush V, andAblin JN.. 
Self-reported childhood maltreatment and traumatic events among Israeli patients suffering from fibromyalgia and rheumatoid arthritis.
Pain Res Manag
2017; 
2017: 3865249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5266864</ArticleId>
            <ArticleId IdType="pubmed">28167861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang MH Hsu JW Huang KL Su TP Bai YM Li CT Yang AC Chang WH Chen TJ Tsai SJ, andChen MH.. 
Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study.
J Pain
2015; 
16: 895–902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26117813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H Kim J Loggia ML Cahalan C Garcia RG Vangel MG Wasan AD Edwards RR, andNapadow V.. 
Fibromyalgia is characterized by altered frontal and cerebellar structural covariance brain networks.
Neuroimage Clin
2015; 
7: 667–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4379388</ArticleId>
            <ArticleId IdType="pubmed">25844321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Häuser W Hoffmann EM Wolfe F Worthing AB Stahl N Rothenberg R, andWalitt B.. 
Self-reported childhood maltreatment, lifelong traumatic events and mental disorders in fibromyalgia syndrome: a comparison of US and German outpatients.
Clin Exp Rheumatol
2015; 
33: S86–S92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4750383</ArticleId>
            <ArticleId IdType="pubmed">25786049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker S, Schweinhardt P.
Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems.
Pain Res Treat
2012; 
2012: 741746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195783</ArticleId>
            <ArticleId IdType="pubmed">22110944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crofford LJ Pillemer SR Kalogeras KT Cash JM Michelson D Kling MA Sternberg EM Gold PW Chrousos GP, andWilder RL.. 
Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia.
Arthritis Rheum
1994; 
37: 1583–1592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7980669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCain GA, Tilbe KS.
Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol Suppl
1989; 
19: 154–157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2607509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ussar S, Fujisaka S, Kahn CR.
Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome.
Mol Metab
2016; 
5: 795–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5004229</ArticleId>
            <ArticleId IdType="pubmed">27617202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordero MD Cano-García FJ Alcocer-Gómez E De Miguel M, andSánchez-Alcázar JA.. 
Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement.
PLoS One
2012; 
7: e35677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3330812</ArticleId>
            <ArticleId IdType="pubmed">22532869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasquez A.
Neuroinflammation in fibromyalgia and CRPS is multifactorial.
Nat Rev Rheumatol
2016; 
12: 242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26935282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szyf M and, Bick J.
DNA methylation: a mechanism for embedding early life experiences in the genome.
Child Dev
2013; 
84: 49–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4039199</ArticleId>
            <ArticleId IdType="pubmed">22880724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denk F and, McMahon SB.
Chronic pain: emerging evidence for the involvement of epigenetics.
Neuron
2012; 
73: 435–444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3996727</ArticleId>
            <ArticleId IdType="pubmed">22325197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang F, Stefano GB and, Kream RM.
Epigenetic modification of DRG neuronal gene expression subsequent to nerve injury: etiological contribution to complex regional pain syndromes (Part II).
Med Sci Monit
2014; 
20: 1188–1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4106931</ArticleId>
            <ArticleId IdType="pubmed">25027291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahn EJ, Guzman-Karlsson MC, David SJ.
Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory.
Neurobiol Learn Mem
2013; 
105: 133–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3769437</ArticleId>
            <ArticleId IdType="pubmed">23796633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seo S Grzenda A Lomberk G Ou XM Cruciani RA, andUrrutia R.. 
Epigenetics: a promising paradigm for better understanding and managing pain.
J Pain
2013; 
14: 549–557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672350</ArticleId>
            <ArticleId IdType="pubmed">23602266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson KD.
DNA methylation and human disease.
Nat Rev Genet
2005; 
6: 597–610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16136652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bestor TH.
The DNA methyltransferases of mammals.
Hum Mol Genet
2000; 
9: 2395–2402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11005794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell JT, Loomis AK, Butcher LM, Gao F, Zhang B, Hyde CL, Sun J, Wu H, Ward K, Harris J, Scollen S, Davies MN, Schalkwyk LC, Mill J; MuTHER Consortium, Williams FM Li N Deloukas P Beck S McMahon SB Wang J John SL, andSpector TD.. 
Differential methylation of the TRPA1 promoter in pain sensitivity.
Nat Commun
2014; 
5: 2978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3926001</ArticleId>
            <ArticleId IdType="pubmed">24496475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fajardo O, Meseguer V, Belmonte C and, Viana F.
TRPA1 channels mediate cold temperature sensing in mammalian vagal sensory neurons: pharmacological and genetic evidence.
J Neurosci
2008; 
28: 7863–7875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6670374</ArticleId>
            <ArticleId IdType="pubmed">18667618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwan KY Allchorne AJ Vollrath MA Christensen AP Zhang DS Woolf CJ, andCorey DP.. 
TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction.
Neuron
2006; 
50: 277–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16630838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies V Lyon DE Archer KJ Zhou Q Brumelle J Jones KH Gao G York TP, andJackson-Cook C.. 
Epigenetic alterations and an increased frequency of micronuclei in women with fibromyalgia.
Nurs Res Pract
2013; 
2013: 795784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3766610</ArticleId>
            <ArticleId IdType="pubmed">24058735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciampi de Andrade D Maschietto M Galhardoni R Gouveia G Chile T Victorino Krepischi AC Dale CS Brunoni AR Parravano DC Cueva Moscoso AS Raicher I Kaziyama HHS Teixeira MJ, andBrentani HP.. 
Epigenetics insights into chronic pain: DNA hypomethylation in fibromyalgia-a controlled pilot-study.
Pain
2017; 
158: 1473–1480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28621701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fatima G, Das SK and, Mahdi AA.
Some oxidative and antioxidative parameters and their relationship with clinical symptoms in women with fibromyalgia syndrome.
Int J Rheum Dis
2017; 
20: 39–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26177214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipowicz W, Bhattacharyya SN and, Sonenberg N.
Mechanisms of post-transcriptional regulation by microRNAs: are the answers insight?
Nat Rev Genet
2008; 
9: 102–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18197166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis BP, Burge CB and, Bartel DP.
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.
Cell
2005; 
120: 15–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15652477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baek D Villén J Shin C Camargo FD Gygi SP, andBartel DP.. 
The impact of microRNAs on protein output.
Nature
2008; 
455: 64–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2745094</ArticleId>
            <ArticleId IdType="pubmed">18668037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rayner KJ and, Hennessy EJ.
Extracellular communication via microRNA: lipid particles have a new message.
J Lipid Res
2013; 
54: 1174–1181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3622315</ArticleId>
            <ArticleId IdType="pubmed">23505318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen HH, Duroux M and, Gazerani P.
MicroRNA as modulators and biomarkers of inflammatory and neuropathic pain conditions.
Neurobiol Dis
2014; 
71: 159–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25119878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartel DP.
MicroRNAs: genomic, biogenesis, mechanism, and function.
Cell
2004; 
116: 281–297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14744438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjersing JL, Lundborg C, Bokarewa MI, Mannerkorpi K.
Profile of cerebrospinal microRNAs in fibromyalgia.
PLoS One
2013; 
8: e78762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3808359</ArticleId>
            <ArticleId IdType="pubmed">24205312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosek E, Ekholm J and, Nordemar R.
A comparison of pressure pain thresholds in different tissues and body regions. Long-term reliability of pressure algometry in healthy volunteers. Scand J Rehabil Med
1993; 
25: 117–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8248762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burckhardt CS, Clark SR and, Bennett RM.
The fibromyalgia impact questionnaire: development and validation.
J Rheumatol
1991; 
18: 728–733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1865419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ericsson A and, Mannerkorpi K.
Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20.
Disabil Rehabil
2007; 
29: 1665–1670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17852297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjersing JL, Bokarewa MI and, Mannerkorpi K.
Profile of circulating microRNAs in fibromyalgia and their relation to symptom severity: an exploratory study.
Rheumatol Int
2015; 
35: 635–642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25261961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozomara A, Griffiths-Jones S.
miRBase: annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res
2014; 
42: D68–D73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3965103</ArticleId>
            <ArticleId IdType="pubmed">24275495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths-Jones S.
The microRNA registry.
Nucleic Acids Res
2004; 
32: D109–D111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC308757</ArticleId>
            <ArticleId IdType="pubmed">14681370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerdá-Olmedo G Mena-Durán AV Monsalve V, andOltra E.. 
Identification of a MicroRNA signature for the diagnosis of fibromyalgia.
PloS One
2015; 
10: e0121903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4372601</ArticleId>
            <ArticleId IdType="pubmed">25803872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masotti A Baldassarre B Guzzo MP Iannuccelli C Barbato C, andDi Franco M.. 
Circulating microRNA profiles as liquid biopsies for the characterization and diagnosis of fibromyalgia syndrome.
Mol Neurobiol
2017; 
54: 7129–7136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27796750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Boer HC van Solingen C Prins J Duijs JM Huisman MV Rabelink TJ, andvan Zonneveld AJ.. 
Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.
Eur Heart J
2013; 
34: 3451–3457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23386708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chhabra R, Dubey R and, Saini N.
Cooperative and individualistic functions of the microRNAs in the miR-23a∼27a∼24-2 cluster and its implication in human diseases.
Mol Cancer
2010; 
9: 232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2940846</ArticleId>
            <ArticleId IdType="pubmed">20815877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wada S Kato Y Sawada S Aizawa K Park JH Russell AP Ushida T, andAkimoto T.. 
MicroRNA-23a has minimal effect on endurance exercise-induced adaptation of mouse skeletal muscle.
Pflugers Arch
2015; 
467: 389–398.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24756198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricketts MD, Han J, Szurgot M, Marmorstein R. Molecular basis for chromatin assembly and modification by multi‐protein complexes. Protein Sci Epub ahead of print 23 October 2018. 
DOI:
10.1002/pro.3535.</Citation>
        </Reference>
        <Reference>
          <Citation>Unal E Arbel-Eden A Sattler U Shroff R Lichten M Haber JE, andKoshland D.. 
DNA damage response pathway uses histone modification to assemble a double-strand break-specific cohesin domain.
Mol Cell
2004; 
16: 991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15610741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karlić R Chung HR Lasserre J Vlahoviček K, andVingron M.. 
Histone modification levels are predictive for gene expression.
Proc Natl Acad Sci
2010; 
107: 2926–2931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2814872</ArticleId>
            <ArticleId IdType="pubmed">20133639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fraga MF, Esteller M.
Epigenetics and aging: the targets and the marks.
Trends Genet
2007; 
23: 413–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17559965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo MH and, Allis CD.
Roles of histone acetyltransferases and deacetylases in gene regulation.
Bioessays
1998; 
20: 615–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9780836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiechio S, Zammataro M and, Morales ME.
Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain.
Mol Pharmacol
2009; 
75: 1014–1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19255242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung YL Lee MY Wang AJ, andYao LF.. 
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
Mol Ther
2003; 
8: 707–717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14599803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leoni F Zaliani A Bertolini G Porro G Pagani P Pozzi P Donà G Fossati G Sozzani S Azam T Bufler P Fantuzzi G Goncharov I Kim SH Pomerantz BJ Reznikov LL Siegmund B Dinarello CA, andMascagni P.. 
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Proc Natl Acad Sci U S A
2002; 
99: 2995–3000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC122461</ArticleId>
            <ArticleId IdType="pubmed">11867742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones KD Gelbart T Whisenant TC Waalen J Mondala TS Iklé DN Salomon DR Bennett RM, andKurian SM.. 
Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia. Clin Exp Rheumatol
2016; 
34: 89–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4888802</ArticleId>
            <ArticleId IdType="pubmed">27157394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connor K, Sabat R, Friedrich M, Volk HD, Sterry W.
Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis.
Curr Drug Targets Inflamm Allergy
2004; 
3:185–192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15180472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connor TM O’Connell J O’Brien DI Goode T Bredin CP, andShanahan F.. 
The role of substance P in inflammatory disease. J Cell Physiol
2004; 
201: 167–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15334652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T Schwander Sk Donnelly R Ortega F Togo F Broderick G Yamamoto Y Cherniack NS Rapoport D, andNatelson BH.. 
Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia.
Clin Vaccine Immunol
2010; 
17: 582–587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2849324</ArticleId>
            <ArticleId IdType="pubmed">20181767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montana MC and, Gereau RW.
Metabotropic glutamate receptors as targets for analgesia: antagonism, activation, and allosteric modulation. Curr Pharm Biotechnol
2011; 
12: 1681–1688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3678530</ArticleId>
            <ArticleId IdType="pubmed">21466446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Razin A, Szyf M.
DNA methylation patterns. Formation and function.
Biochim Biophys Acta
1984; 
782; 331–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6383476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massart R Dymov S Millecamps M Suderman M Gregoire S Koenigs K Alvarado S Tajerian M Stone LS, andSzyf M.. 
Overlapping signatures of chronic pain in the DNA methylation landscape of prefrontal cortex and peripheral T cells.
Nature
2016; 
6: 19615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4730199</ArticleId>
            <ArticleId IdType="pubmed">26817950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tylee DS, Kawaguchi DM, Glatt SJ.
On the outside, looking in: A review and evaluation of the comparability of blood and brain “-omes”. Am J Med Genet
2013; 
162B: 595–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24132893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xenon Pharmaceuticals Inc. A phase 2a, randomized, double-blind, placebo-controlled, two-period crossover study to evaluate the safety, tolerability, preliminary efficacy, and systemic exposure of topical XPF-002 in subjects with postherpetic neuralgia,  https://ichgcp.net/clinical-trials-registry/NCT01195636 </Citation>
        </Reference>
        <Reference>
          <Citation>Xenon Pharmaceuticals Inc. Phase 2a, exploratory, double-blind, placebo-controlled two-part study to evaluate the safety, efficacy, tolerability and pharmacokinetics of topically applied XPF-002 (XEN402 8% w/w Ointment) in patients with primary/inherited erythromelalgia, http://clinicaltrials.gov/ct2/show/NCT01486446?term=xen402&amp;rank=2</Citation>
        </Reference>
        <Reference>
          <Citation>Biogen. A randomized, double blind, cross-over study to evaluate the safety and efficacy of CNV1014802 in subjects with neuropathic pain from lumbosacral radiculopathy, http://clinicaltrials.gov/ct2/show/NCT01561027?term=CNV1014802&amp;rank=2</Citation>
        </Reference>
        <Reference>
          <Citation>Crow M, Denk F and, McMahon SB.
Genes and epigenetic processes as prospective pain targets.
Genome Med
2013; 
5: 12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3706821</ArticleId>
            <ArticleId IdType="pubmed">23409739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y Liu C Guo QL Yan JQ Zhu XY Huang CS, andZou WY.. 
Intrathecal 5-azacytidine inhibits global DNA methylation and methyl-CpG-binding protein 2 expression and alleviates neuropathic pain in rats following chronic constriction injury.
Brain Res
2011; 
1418: 64–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21925646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szyf M.
Epigenetics, DNA methylation, and chromatin modifying drugs.
Annu Rev Pharmacol Toxicol
2009; 
49: 243–263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18851683</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
